Hyperlipidemia in Children and Adolescents.

Area of Science:

• Pediatrics
• Cardiology
• Genetics

Background:

• Atherosclerosis, typically seen in adults, can begin in childhood.
• Childhood dyslipidemia is a significant risk factor for early-onset coronary artery disease (CAD).
• Limited randomized controlled trials exist for pediatric dyslipidemia treatment.

Purpose of the Study:

• To review current understanding and treatment strategies for dyslipidemia in children and adolescents.
• To highlight the association between childhood dyslipidemia and accelerated CAD.
• To emphasize the importance of early screening and intervention.

Main Methods:

• Review of recent guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA).
• Analysis of contributing factors including genetics, environment, obesity, and lifestyle.
• Discussion of multimodal treatment approaches, including lifestyle modifications and pharmacotherapy.

Main Results:

• Childhood dyslipidemia is associated with increased lipid levels and earlier CAD.
• Familial hyperlipidemia affects approximately 1 in 250 individuals.
• Multimodal treatment, combining diet, exercise, and medication, is most effective.

Conclusions:

• Early detection and management of dyslipidemia in children and adolescents are crucial for preventing premature CAD.
• Pharmacologic interventions, including statins, evolocumab, and evinacumab, play a key role, particularly for genetic forms.
• A comprehensive approach integrating lifestyle changes and medication is recommended for optimal outcomes.